Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sertraline for the Treatment of Major Depressive Disorder in the US: Effectiveness and Acceptability in Real-World Practice.

Neuropsychiatric disease and treatment·2026
Same author

Understanding treatment patterns and patient-reported outcomes associated with the use of authorized generics and corresponding independent generics across multiple therapeutic areas.

Current medical research and opinion·2022
Same author

New Strategies to Improve Patient Adherence to Medications for Noncommunicable Diseases During and After the COVID-19 Era Identified via a Literature Review.

Journal of multidisciplinary healthcare·2021
Same author

Comment on "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US".

PharmacoEconomics·2020
Same author

How excluding some benefits from value assessment of new drugs impacts innovation.

Health economics·2017
Same author

Risk-based decision making and ethical considerations in donor compensation for plasma-derived medicinal products.

Transfusion·2016
Same journal

Balancing Access and Value in Multi-Indication Medicines: Implications of PD-L1 Broad Listings in Australia.

PharmacoEconomics·2026
Same journal

Applications of Structural Expert Elicitations for Economic Evaluations: A Systematic Review Update.

PharmacoEconomics·2026
Same journal

Community Pharmacist Preferences for Providing a Dose Administration Aid Service in Australia: A Discrete Choice Experiment.

PharmacoEconomics·2026
Same journal

A Critical Systematic Review of Modelling Approaches and Methodologies used in Hyperlipidaemia Economic Evaluations.

PharmacoEconomics·2026
Same journal

Deriving a Korean SF-6Dv2 Value Set Using a Discrete Choice Experiment with Duration.

PharmacoEconomics·2026
Same journal

Correction: Ten Recommendations for Modelling Cost Effectiveness of Screening: Perspectives of an International Stakeholder Group.

PharmacoEconomics·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Pharmaceutical risk-sharing agreements.

Joseph P Cook1, John A Vernon, Richard Manning

  • 1NERA Economic Consulting, White Plains, NY, USA.

Pharmacoeconomics
|June 20, 2008
PubMed
Summary
This summary is machine-generated.

Pharmaceutical companies can build trust and justify high drug prices by sharing financial risk. Risk-sharing agreements, similar to warranties, can signal product quality and potentially lower healthcare costs.

Related Experiment Videos

Last Updated: Jul 4, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Healthcare Management

Background:

  • Rising pharmaceutical expenditure is a significant concern in healthcare policy debates.
  • While increased utilization drives costs, appropriate drug use can reduce overall healthcare spending.
  • Perception of high drug prices necessitates strategies for pharmaceutical companies to demonstrate value.

Purpose of the Study:

  • To explore risk-sharing arrangements as a mechanism for pharmaceutical companies to build confidence in product value.
  • To examine how risk-sharing can align incentives between manufacturers, consumers, and payers.
  • To assess the potential of risk-sharing to signal pharmaceutical quality in an uncertain market.

Main Methods:

  • Conceptual analysis of pharmaceutical market dynamics and value demonstration strategies.
  • Review of existing and potential risk-sharing models in the pharmaceutical sector.
  • Economic evaluation of warranty-like arrangements for pharmaceuticals.

Main Results:

  • Risk-sharing agreements can serve as a quality signal when product effectiveness is uncertain.
  • These arrangements can help justify higher drug prices by linking payment to outcomes.
  • Potential for risk-sharing to become a standard market feature, improving investment incentives.

Conclusions:

  • Pharmaceutical risk-sharing offers a novel approach to address concerns about drug pricing and value.
  • Implementing such schemes can enhance market confidence and encourage innovation.
  • Further development and adoption of risk-sharing models are anticipated in the future.